Dashenlin

2022 Informatization of China's Rehabilitation Industry

The rehabilitation industry caught the attention of the Chinese government again in 2021, and the industry entered a phase of accelerated development. The rehabilitation industry will first supplement medical resources and continue to explore a rehabilitation model that suits China's actual conditions. Under this context, EqualOcean Intelligence, together with Neusoft Group, released the 2022 Research Report On the Informatization of China's Rehabilitation Industry.

Challenges and Opportunities Possessed by Digital Therapeutics Industry

Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.

EqualOcean 2022 China AI Health 30 Companies list Reveals

Starting from September 2022, EqualOcean had been conducting deep market research and expert interviews aiming to select out 30 most representative China-based companies in the AI Health sector that are with the most growth and development potential. It is finally officially finalized, and we give our deep and sincere congratulations to those 30 companies and wish them all the best in the future.

Dissection of Applications of AI in China’s Healthcare Industry

As AI enables automatic problem-solving and is highly intelligence, it can be applied to a wide variety of fields in the healthcare, especially for the labour intensive tasks. In China, from the basic medical health records to the complex disease treatment planning and prediction, you can always find the involvement of AI. Here, we choose seven sectors with more mature development and introduced them.

IND Approval for Yuyuan Bioscience’s Phase I Clinical Trial of Nolasiban in China

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy.